{
    "name": "fenofibrate",
    "comment": "Rx",
    "other_names": [
        "Tricor",
        "Lofibra tablets",
        "Fenoglide",
        "Lipofen",
        "Triglide"
    ],
    "classes": [
        "Fibric Acid Agents"
    ],
    "source": "https://reference.medscape.com/drug/tricor-lofibra-tablets-fenofibrate-342451",
    "pregnancy": {
        "common": [
            "Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration in rats and rabbits during organogenesis at doses less than or equivalent to the maximum recommended clinical dose of 120 mg daily, based on body surface area (mg/m2)",
                    "Adverse reproductive outcomes occurred at higher doses in presence of maternal toxicity; drug should be used during pregnancy only if potential benefit justifies potential risk to fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no available information on presence of drug in human milk, effects on the breastfed infant, or on milk production; drug is present in milk of rats, and likely to be present in human milk; because of potential for serious adverse reactions in breastfed infants, such as disruption of infant lipid metabolism, women should not breastfeed during treatment and for 5 days after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity",
                "Severe renal impairment, including those with end-stage renal disease and those receiving dialysis",
                "Active liver disease",
                "Gallbladder disease",
                "Nursing mothers"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cholelithiasis reported with use; discontinue if gallstones detected upon gallbladder studies",
                "Rare myopathy, myositis, or rhabdomyolysis reported with use; monitor",
                "Increase in hepatic transaminases reported; discontinue if enzyme levels persist 3 times above the upper limit of normal",
                "Reversibly increases serum creatinine levels; consider monitoring renal function in patients at risk for renal impairment",
                "Thrombocytopenia and agranulocytosis reported; monitor blood counts periodically during the first year of therapy",
                "Associated with pulmonary embolism and deep venous thrombosis; use caution in patients with risk factors for VTE",
                "Concomitant use with oral anticoagulants (monitor and adjust warfarin dose prn)",
                "May further increase risk for rhabdomyolysis when added to optimal HMG-CoA reductase inhibitor regimen to further decrease TG and increase HDLs",
                "Paradoxical decreases in HDL cholesterol (HDL-C) level reported",
                "Rule out secondary causes of hyperlipidemia before initiating therapy",
                "Withdraw therapy if no adequate response seen after 2-3 months",
                "Use with caution in the elderly; dose adjustments may be necessary",
                "Fenofibrate increases cholesterol excretion into bile, leading to risk of cholelithiasis; perform gallbladder studies if cholelithiasis suspected",
                "Fibric acid derivatives as monotherapy or in combination with simvastatin have not been shown to significantly reduce cardiovascular mortality in major clinical studies"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "fenofibrate, atorvastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colchicine",
            "description": {
                "common": "colchicine, fenofibrate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (incl a fatality)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "fenofibrate, fluvastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lovastatin",
            "description": {
                "common": "fenofibrate, lovastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pitavastatin",
            "description": {
                "common": "fenofibrate, pitavastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pravastatin",
            "description": {
                "common": "fenofibrate, pravastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "fenofibrate, rosuvastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "simvastatin",
            "description": {
                "common": "fenofibrate, simvastatin.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol will increase the level or effect of fenofibrate by  Other (see comment). Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit UGT1A9 activity. Consider reducing the dose when concomitantly using UGT1A9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "fenofibrate increases effects of chlorpropamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of fenofibrate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholic acid",
            "description": {
                "common": "fenofibrate increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "fenofibrate increases levels of cyclosporine by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix decreases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "fenofibrate increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "fenofibrate increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "fenofibrate increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone increases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "fenofibrate increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "fenofibrate, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "fenofibrate, insulin degludec/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "fenofibrate increases effects of insulin detemir by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "fenofibrate increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "fenofibrate increases effects of insulin glulisine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "fenofibrate, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "fenofibrate increases effects of insulin lispro by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "fenofibrate increases effects of insulin NPH by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "fenofibrate increases effects of insulin regular human by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mavacamten",
            "description": {
                "common": "fenofibrate will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, fenofibrate. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "fenofibrate increases levels of tenofovir DF by decreasing renal clearance. Use Caution/Monitor. Increased risk of myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "fenofibrate increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "fenofibrate increases effects of tolbutamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "fenofibrate will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Mechanism of interaction may be caused by CYP2C9 inhibition and protein-binding displacement. "
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol decreases levels of fenofibrate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ezetimibe",
            "description": {
                "common": "fenofibrate increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "octacosanol",
            "description": {
                "common": "octacosanol increases effects of fenofibrate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of fenofibrate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Increased LFT",
            "percent": "3-13"
        },
        {
            "name": "s",
            "percent": "6"
        },
        {
            "name": "dose related",
            "percent": "5"
        },
        {
            "name": "Respiratory disorder",
            "percent": "3"
        },
        {
            "name": "Abdominal pain",
            "percent": "3"
        },
        {
            "name": "Back pain",
            "percent": "3"
        },
        {
            "name": "CPK increased",
            "percent": "2"
        },
        {
            "name": "Headache",
            "percent": "2"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "Muscle pain",
            "percent": null
        },
        {
            "name": "Myopathies",
            "percent": null
        },
        {
            "name": "Myositis",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Peptic ulcer",
            "percent": null
        },
        {
            "name": "Cholelithiasis",
            "percent": null
        },
        {
            "name": "CNS depression",
            "percent": null
        },
        {
            "name": "Dysrhythmias",
            "percent": null
        },
        {
            "name": "Peripheral vascular disease",
            "percent": null
        },
        {
            "name": "Pulmonary embolus",
            "percent": null
        },
        {
            "name": "Renal damage",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        }
    ]
}